Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHC NASDAQ:ANIP NASDAQ:ARQT NASDAQ:LCAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHCAcadia Healthcare$21.76-2.5%$22.13$17.13▼$79.82$2.00B0.892.23 million shs1.50 million shsANIPANI Pharmaceuticals$98.06-0.7%$78.87$52.50▼$99.50$2.13B0.63374,955 shs100,686 shsARQTArcutis Biotherapeutics$17.35-1.9%$15.40$8.03▼$18.15$2.10B1.932.08 million shs1.03 million shsLCAPLionheart Acquisition Co. II$28.61+1.1%$10.38$8.94▼$11.70$527.92M0.08102,067 shs12,076 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHCAcadia Healthcare+5.94%-5.67%+9.74%+5.09%-71.07%ANIPANI Pharmaceuticals+1.30%+2.84%+11.76%+57.82%+81.76%ARQTArcutis Biotherapeutics+0.68%+9.13%+20.01%+31.72%+68.16%LCAPLionheart Acquisition Co. II+0.27%+1.43%+3.18%+7.59%+16,751.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHCAcadia Healthcare$21.76-2.5%$22.13$17.13▼$79.82$2.00B0.892.23 million shs1.50 million shsANIPANI Pharmaceuticals$98.06-0.7%$78.87$52.50▼$99.50$2.13B0.63374,955 shs100,686 shsARQTArcutis Biotherapeutics$17.35-1.9%$15.40$8.03▼$18.15$2.10B1.932.08 million shs1.03 million shsLCAPLionheart Acquisition Co. II$28.61+1.1%$10.38$8.94▼$11.70$527.92M0.08102,067 shs12,076 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHCAcadia Healthcare+5.94%-5.67%+9.74%+5.09%-71.07%ANIPANI Pharmaceuticals+1.30%+2.84%+11.76%+57.82%+81.76%ARQTArcutis Biotherapeutics+0.68%+9.13%+20.01%+31.72%+68.16%LCAPLionheart Acquisition Co. II+0.27%+1.43%+3.18%+7.59%+16,751.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHCAcadia Healthcare 2.62Moderate Buy$39.0079.25% UpsideANIPANI Pharmaceuticals 3.10Buy$88.25-10.00% DownsideARQTArcutis Biotherapeutics 2.86Moderate Buy$19.8014.11% UpsideLCAPLionheart Acquisition Co. II 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LCAP, ACHC, ARQT, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025ACHCAcadia HealthcareBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$27.00 ➝ $25.009/8/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$86.00 ➝ $114.008/21/2025ANIPANI PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025ACHCAcadia HealthcareRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Outperform$40.00 ➝ $26.008/13/2025ACHCAcadia HealthcareMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $22.008/13/2025ACHCAcadia HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$43.00 ➝ $28.008/11/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$65.00 ➝ $77.008/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.008/7/2025ARQTArcutis BiotherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025ACHCAcadia HealthcareCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHCAcadia Healthcare$3.23B0.62$5.10 per share4.27$33.09 per share0.66ANIPANI Pharmaceuticals$747.40M2.85$7.64 per share12.83$19.11 per share5.13ARQTArcutis Biotherapeutics$196.54M10.59N/AN/A$1.35 per share12.85LCAPLionheart Acquisition Co. IIN/AN/A$1.39 per share20.64($2.85) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHCAcadia Healthcare$255.61M$1.5114.336.424.144.31%8.34%4.20%10/29/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$0.77N/A23.29N/A-1.37%25.03%8.00%11/14/2025 (Estimated)ARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%11/5/2025 (Estimated)LCAPLionheart Acquisition Co. II$3.21MN/A0.00∞N/AN/A-44.30%1.39%N/ALatest LCAP, ACHC, ARQT, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million8/5/2025Q2 2025ACHCAcadia Healthcare$0.71$0.83+$0.12$0.33$839.59 million$869.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHCAcadia HealthcareN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ALCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHCAcadia Healthcare0.731.321.32ANIPANI Pharmaceuticals1.392.541.96ARQTArcutis Biotherapeutics0.773.203.04LCAPLionheart Acquisition Co. IIN/A0.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHCAcadia HealthcareN/AANIPANI Pharmaceuticals76.05%ARQTArcutis BiotherapeuticsN/ALCAPLionheart Acquisition Co. IIN/AInsider OwnershipCompanyInsider OwnershipACHCAcadia Healthcare1.30%ANIPANI Pharmaceuticals11.10%ARQTArcutis Biotherapeutics9.40%LCAPLionheart Acquisition Co. II19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHCAcadia Healthcare25,50092.35 million91.15 millionOptionableANIPANI Pharmaceuticals60021.70 million19.29 millionOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableLCAPLionheart Acquisition Co. II318.45 million14.87 millionNot OptionableLCAP, ACHC, ARQT, and ANIP HeadlinesRecent News About These CompaniesRF Acquisition Corp IISeptember 13, 2024 | morningstar.comMLionheart Holdings - Ordinary Shares - Class AAugust 13, 2024 | money.usnews.comLionheart Capital Plans $1B Lakeside Mall Redevelopment in Sterling Heights, MichiganMay 2, 2024 | rebusinessonline.comRMount Logan Capital Inc. Announces Entry into Business Combination With Canaccord Genuity G Ventures Corp.August 14, 2023 | markets.businessinsider.comMarwyn Acquisition Co. II Names Will Self as New CEOJune 6, 2023 | marketwatch.comLF Capital Acquisition Corp. II Provides Update Regarding Potential Business CombinationJune 2, 2023 | technews.tmcnet.comFrance Receives $47M in Funding From LVMH and Acquires Caillebotte PaintingJanuary 31, 2023 | news.yahoo.comPeraton Subsidiary Books $343M TSA Contract for IT Support; John Coleman QuotedDecember 21, 2022 | executivegov.comERevolution Healthcare Acquisition Corp. Will Redeem Public SharesNovember 28, 2022 | yahoo.comAcasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12, 2022 | finance.yahoo.comMSP RECOVERY INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at MSP Recovery Inc.June 2, 2022 | apnews.comAMSP Recovery shares plunge 64% following merger with SPAC LionheartMay 24, 2022 | seekingalpha.comSPAC Lionheart Acquisition Corp. II shareholders approve MSP Recovery mergerMay 19, 2022 | seekingalpha.comLionheart Acquisition Corporation II Shareholders Approve Previously Announced Business Combination with MSP RecoveryMay 18, 2022 | finance.yahoo.comCEO defends $800,000 NIL deal with college athlete: ‘We're going to be on everybody's minds'May 17, 2022 | finance.yahoo.comMSP Recovery Sees Substantial Business Expansion Since Announcement of Its Business Combination Through Development of Additional Revenue Streams, MonMay 17, 2022 | us.acrofan.comUMSP Recovery Sees Substantial Business Expansion Since AnnouncementMay 17, 2022 | tmcnet.comMSP Recovery Sees Substantial Business Expansion Since Announcement of Its Business Combination Through Development of Additional Revenue Streams, Monetization of Assignor Interests, Growth of Existing Business, and Continued InnovationMay 17, 2022 | finance.yahoo.comLionheart Acquisition Corporation II Enters into Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald L.P.May 13, 2022 | finance.yahoo.comSPAC Lionheart gets 6 months extension to complete deal with MSP RecoveryJanuary 31, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCAP, ACHC, ARQT, and ANIP Company DescriptionsAcadia Healthcare NASDAQ:ACHC$21.76 -0.55 (-2.48%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.ANI Pharmaceuticals NASDAQ:ANIP$98.06 -0.67 (-0.68%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Arcutis Biotherapeutics NASDAQ:ARQT$17.35 -0.34 (-1.92%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Lionheart Acquisition Co. II NASDAQ:LCAPLionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
